Bluebird Bio

Is There Any Hope for bluebird bio Stock?

Zhiyuan Sun | Feb 24, 2021

Investors are ditching this gene therapy stock en masse, for good reason.

---

Why bluebird bio Stock Is Plunging Today

Prosper Junior Bakiny | Feb 16, 2021

The company had to halt one of its clinical studies following a suspected severe adverse reaction.

---

bluebird bio to Spin Off Its Oncology Business

Cory Renauer | Jan 11, 2021

The biotech will then focus on its rare disease programs.

---

Here Are the 2 Best Biotech Stocks in This Multibillion-Dollar Industry

Brian Orelli, PhD | Dec 23, 2020

The hematology space is hot.

---

ASH Annual Meeting: Drugmakers Battle for Multiple Myeloma

Brian Orelli, PhD | Dec 13, 2020

Targeting BCMA is all the rage, but who will come out on top?

---

Watch Out bluebird bio, CRISPR Is on Your Heels

Brian Orelli, PhD | Dec 12, 2020

The battle for beta thalassemia and sickle cell disease patients is heating up.

---

3 Stocks That Are Giving Their Investors Coal in Their Stockings

Jason Hawthorne | Dec 12, 2020

Naughty or nice, shareholders aren't getting anything on their wish lists from these stocks this year.

---

Can bluebird bio Recover From Another Major Setback?

Cory Renauer | Nov 6, 2020

Another manufacturing issue set the biotech's sickle cell disease program back much further than investors had hoped.

---

Here's Why Bluebird's Shares Fell Out of the Nest Today

Brian Orelli, PhD | Nov 5, 2020

A delay in submitting its sickle cell treatment to the FDA will push back a major source of future revenue.

---

Got $500? Here Are 2 Stocks That Could Soar

Prosper Junior Bakiny | Oct 4, 2020

The road ahead may be a bit rocky, but investing in these companies may pay off big-time -- eventually.

---

The Top Biotech Stocks to Watch Following ASH 2019

Todd Campbell | Dec 19, 2019

The potential to reshape treatment of blood cancer and disorders could mean big bucks for these companies.

---

Why bluebird bio Stock Is Plunging Today

Prosper Junior Bakiny | Feb 16, 2021

The company had to halt one of its clinical studies following a suspected severe adverse reaction.

---

Here's Why Bluebird's Shares Fell Out of the Nest Today

Brian Orelli, PhD | Nov 5, 2020

A delay in submitting its sickle cell treatment to the FDA will push back a major source of future revenue.

---

Why bluebird bio Stock Soared Today

Keith Speights | Apr 9, 2020

A major move by the Fed lifted the entire stock market, including this biotech stock.

---

Here’s Why bluebird bio Shares Jumped Almost 12% Today

Brian Orelli, PhD | Dec 10, 2019

Solid data from the biggest blood disease meeting of the year has the biotech flying high.

---

Here's Why bluebird bio Fell 21.3% in August

Maxx Chatsko | Sep 9, 2019

Wall Street has soured on the company's prospects as it eyes a transition to commercial operations.

---

Here's Why Shares of bluebird bio Slumped Today

Brian Orelli, PhD | Apr 17, 2019

No-news anxiety-selling seems to be to blame for the biotech's woes.

---

Here's Why bluebird bio Gained 16.3% in February

Maxx Chatsko | Mar 11, 2019

The biopharma announced fourth-quarter 2018 operating results and reminded investors of its deep late-state pipeline.

---

Here's What Pushed bluebird bio Stock Down 44.3% in 2018

Cory Renauer | Jan 12, 2019

Disappointing drug launches for expensive, single-application treatments poured water on otherwise impressive progress.

---

Here's Why bluebird bio Shares Got Knocked Down 19.3% in December

Todd Campbell | Jan 4, 2019

Data presented by a competitor increased the risk to its most promising clinical-stage therapy.

---

Here's Why bluebird bio Fell 21.4% in October

Maxx Chatsko | Nov 7, 2018

In September and October, investors thought Amgen set the bar in multiple myeloma too high, but in November bluebird bio teased promising data of its own.

---